Maze Therapeutics (NASDAQ:MAZE) Shares Up 8.5% – What’s Next?

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) rose 8.5% on Tuesday . The stock traded as high as $48.84 and last traded at $48.88. Approximately 281,980 shares changed hands during mid-day trading, a decline of 35% from the average daily volume of 432,037 shares. The stock had previously closed at $45.06.

Analysts Set New Price Targets

Several research firms have recently commented on MAZE. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price for the company. Raymond James Financial assumed coverage on shares of Maze Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price on the stock. Finally, Guggenheim increased their target price on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $54.63.

Maze Therapeutics Stock Up 3.6%

The stock has a fifty day moving average price of $44.40 and a two-hundred day moving average price of $35.22. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of -2.48 and a beta of 4.47.

Insider Buying and Selling

In related news, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $44.27, for a total transaction of $332,025.00. Following the completion of the transaction, the insider directly owned 10,503 shares in the company, valued at $464,967.81. This represents a 41.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Amy Bachrodt sold 5,000 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $46.04, for a total value of $230,200.00. Following the completion of the sale, the senior vice president directly owned 12,965 shares in the company, valued at approximately $596,908.60. This represents a 27.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 200,000 shares of company stock worth $8,254,792.

Institutional Trading of Maze Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd purchased a new position in shares of Maze Therapeutics in the fourth quarter worth $145,000. Invesco Ltd. increased its stake in shares of Maze Therapeutics by 1.5% in the 4th quarter. Invesco Ltd. now owns 134,033 shares of the company’s stock worth $5,553,000 after purchasing an additional 1,971 shares in the last quarter. ADAR1 Capital Management LLC lifted its position in Maze Therapeutics by 589.3% during the fourth quarter. ADAR1 Capital Management LLC now owns 179,532 shares of the company’s stock valued at $7,438,000 after purchasing an additional 153,487 shares in the last quarter. XTX Topco Ltd grew its holdings in Maze Therapeutics by 22.9% during the fourth quarter. XTX Topco Ltd now owns 33,021 shares of the company’s stock valued at $1,368,000 after purchasing an additional 6,154 shares during the period. Finally, Wellington Management Group LLP bought a new position in shares of Maze Therapeutics in the fourth quarter worth about $2,536,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.